Ghyass Rizk, MD
Endocrinology, Diabetes & Metabolism · Lafayette, LANPI 1144267360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 793 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,782 and has fallen 74.3% since, to $972 in 2025.
Across 793 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$2K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AstraZeneca$1K
- Esperion Therapeutics, Inc.$750
- AbbVie$685
- plus $7K from 42 others
What the payments were for
- Food & beverage$16,332100%
- Education$650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$1,053
- Ozempic$350
- DEXCOM CGM$315
- DEXCOM G6 TRANSMITTER$278
- FARXIGA$249
- NEXLIZET$237
- NEXLETOL$237
- INVOKANA$232
- SOLIQUA 100/33$226
- EVENITY$122
- RYBELSUS$122
- Kerendia$122
- MINIMED 780G$116
- Wegovy$115
- JARDIANCE$113
- TOUJEO$112
- QUVIVIQ$111
- NATPARA (PARATHYROID HORMONE)$109
- Synthroid$106
How this compares
$16,397 in reported general payments places this provider in the 75th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 203 | $245,230 |
| OzempicSemaglutide | 94 | $113,522 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 61 | $43,978 |
| JardianceEmpagliflozin | 34 | $40,333 |
| FiaspInsulin Aspart (Niacinamide) | 35 | $35,731 |
| FarxigaDapagliflozin Propanediol | 35 | $28,330 |
| JanuviaSitagliptin Phosphate | 19 | $17,598 |
| TrulicityDulaglutide | 14 | $15,467 |
| NovologInsulin Aspart | 48 | $13,567 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $11,900 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $11,382 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $11,323 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $10,782 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 26 | $9,080 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $8,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $2,033 | $268,057275 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $2,231 | $162,820177 claims |
| Boehringer IngelheimJardiance | $580 | $40,33334 claims |
| AstraZenecaFarxiga | $1,025 | $28,33035 claims |
| MerckJanuvia | $163 | $17,59819 claims |
| AbbVieSynthroid, Armour Thyroid | $685 | $9,053148 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $188 | $4,511554 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $110 | $2,40188 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Lafayette
- Justin FontenotLafayette$397K
- Bennett BaquetLafayette$30K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.